PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court.

A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...

Independent Advisor Alliance bought a new position in shares of Insulet Co. (NASDAQ:PODD – Free Report) during the 3rd ...

With a market cap of $18.4 billion, Insulet Corporation (PODD) is a global leader in developing innovative insulin delivery ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...